Applications · US

OpenEvidence was valued at $15B as of 25 September 2026 (reported). Source: Axios Pro, OpenEvidence reportedly raises $250M at $15B valuation (Byers Capital and Andreessen Horowitz).

Clinical decision search for physicians; fastest-growing medical AI, used by about 40% of US doctors and consulted 42 million times in August 2026 alone.

Valuation

$15B

Confidence

reported

As of

25 September 2026

Layer

Applications

Signal

clinical search

Website

openevidence.com

Relationships (2)

Valuation history on the map

Date	Mark	Change
26 September 2026	$15B	+25.0%
27 July 2026	$12B

Daily snapshots began 27 July 2026. Public companies move with the market every weekday.

Notes

Clinical decision search for physicians; fastest-growing medical AI, used by about 40% of US doctors and consulted 42 million times in August 2026 alone. A $250M round reported on 2026-09-25 marks it at $15B, up 25% from the January Series D and roughly 50x its ~$300M annualised revenue; Byers Capital and Andreessen Horowitz are named as leads. Neither the company nor a lead has published the round, so the mark is reported rather than verified - the July 2026 report of a $200M round at $20B (The Information) was said to be unlikely to proceed on dilution grounds, and the company has separately been described as weighing a sale. Alongside the round the CEO told Forbes that OpenEvidence is moving into drug development, aiming to put a first oncology therapy into clinical trials before year-end. On 2026-09-23 it partnered with Anthropic to give doctors in roughly 100 low- and middle-income countries a free version of the product, with Anthropic supplying the model capacity - extending earlier pilots in Rwanda and Botswana.

Sources

• Axios Pro, OpenEvidence reportedly raises $250M at $15B valuation (Byers Capital and Andreessen Horowitz) 2026-09-25
• Business Insider (via Reuters newsfeed), OpenEvidence was valued at $15 billion in a new funding round 2026-09-25
• Prior round: CNBC, OpenEvidence doubles valuation to $12 billion on a $250M Series D co-led by Thrive Capital and DST Global 2026-01-21
• Fierce Healthcare, OpenEvidence clinches $250M Series D, rapidly growing its reach to doctors 2026-01-22

See something wrong or out of date? Suggest a correction (GitHub) or email it. Please include a source.

Last updated 26 September 2026. Follow OpenEvidence in any feed reader to hear when its valuation moves.

State of AI World maps every significant AI company, what it is worth and how it is connected. Every number carries a source and an as-of date; see the methodology. Data is free to reuse with credit: open data. · All companies · Daily digest · Corrections and contact